Trials / Completed
CompletedNCT03723746
A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Day Dose Study to Assess the Safety and Tolerability of JNJ-67670187 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of single and multiple day dose of JNJ-67670187 compared to placebo.
Detailed description
This study will be a Phase 1 randomized double-blind, placebo controlled multi dose study in up to 144 adult healthy volunteers. The safety, tolerability and impact on the microbiome following intake of oral dose of JNJ-67670187 for up to 14 days will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | JNJ-67670187 | Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2. |
| BIOLOGICAL | Placebo | Participants will receive matching placebo in all cohorts. |
Timeline
- Start date
- 2018-10-25
- Primary completion
- 2019-12-16
- Completion
- 2019-12-16
- First posted
- 2018-10-30
- Last updated
- 2020-02-19
Locations
2 sites across 2 countries: Belgium, Netherlands
Source: ClinicalTrials.gov record NCT03723746. Inclusion in this directory is not an endorsement.